Zorevunersen
- Generic Name
- Zorevunersen
- Drug Type
- Biotech
- CAS Number
- 2415330-04-8
- Unique Ingredient Identifier
- U4YV46D2DT
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients with Dravet Syndrome
Phase 3
Not yet recruiting
- Conditions
- Dravet Syndrome
- Interventions
- Other: Sham Comparator
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Stoke Therapeutics, Inc
- Target Recruit Count
- 150
- Registration Number
- NCT06872125
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Stoke Therapeutics, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT04740476
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
Phase 1
Completed
- Conditions
- Dravet Syndrome
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Stoke Therapeutics, Inc
- Target Recruit Count
- 62
- Registration Number
- NCT04442295
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath